Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

655 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Tenorio AR, Pappa KA, Wynne B, Gartland M, Aboud M, van Wyk J, Smith KY. Cahn P, et al. Among authors: girard pm. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318. doi: 10.1097/QAI.0000000000002275. J Acquir Immune Defic Syndr. 2020. PMID: 31834000 Free PMC article. Clinical Trial.
Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study.
Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, Girard PM, Bélarbi L, Guérin C, Dimet J, Williams V, Krivine A, Salmon D, Lortholary O, Rey D; HEPAVAC Study Group1. Launay O, et al. Among authors: girard pm. J Acquir Immune Defic Syndr. 2008 Nov 1;49(3):272-5. doi: 10.1097/QAI.0b013e318183a9c0. J Acquir Immune Defic Syndr. 2008. PMID: 18845961 Clinical Trial.
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team. Yeni P, et al. HIV Med. 2009 Feb;10(2):116-24. doi: 10.1111/j.1468-1293.2008.00660.x. HIV Med. 2009. PMID: 19200175 Free article. Clinical Trial.
CD4-specific mortality rates among HIV-infected adults with high CD4 counts and no antiretroviral treatment in West Africa.
Lewden C, Gabillard D, Minga A, Ekouévi DK, Avit D, Konate I, Amani-Bossé C, Messou E, Coffie P, Ouedraogo A, Laurent C, Anglaret X; ANRS 12222 MorbidityMortality Study Group. Lewden C, et al. J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):213-9. doi: 10.1097/QAI.0b013e31823b837e. J Acquir Immune Defic Syndr. 2012. PMID: 22027874 Free PMC article.
A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.
Moyle GJ, Andrade-Villanueva J, Girard PM, Antinori A, Salvato P, Bogner JR, Hay P, Santos J, Astier L, Pans M, Balogh A, Biguenet S; ReAL Study Team. Moyle GJ, et al. Among authors: girard pm. Antivir Ther. 2012;17(4):689-700. doi: 10.3851/IMP2083. Epub 2012 Mar 2. Antivir Ther. 2012. PMID: 22388634 Clinical Trial.
Tolerability of mefloquine intermittent preventive treatment for malaria in HIV-infected pregnant women in Benin.
Denoeud-Ndam L, Clément MC, Briand V, Akakpo J, Agossou VK, Atadokpédé F, Dossou-Gbété L, Komongui DG, Afangnihoun A, Girard PM, Zannou DM, Cot M. Denoeud-Ndam L, et al. Among authors: girard pm. J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):64-72. doi: 10.1097/QAI.0b013e3182615a58. J Acquir Immune Defic Syndr. 2012. PMID: 22706291 Clinical Trial.
Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration.
Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, Etard JF, Pagnaroat M, Fournier-Nicolle I, Eholié S, Konate I, Minga A, Mpoudi-Ngole E, Koulla-Shiro S, Zannou DM, Anglaret X, Laurent C; ANRS 12222 Morbidity Mortality Study Group. Gabillard D, et al. J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):555-61. doi: 10.1097/QAI.0b013e3182821821. J Acquir Immune Defic Syndr. 2013. PMID: 23274931 Free PMC article.
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.
Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, Gharakhanian S, McCallister S, Henshaw J, Girard PM, Adiwijaya B, Garg V, Rubin RA, Adda N, Soriano V. Sulkowski MS, et al. Among authors: girard pm. Ann Intern Med. 2013 Jul 16;159(2):86-96. doi: 10.7326/0003-4819-159-2-201307160-00654. Ann Intern Med. 2013. PMID: 23685940 Clinical Trial.
655 results